A5006624449- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- RNA modifications and cancer
- Molecular Biology Techniques and Applications
- Lung Cancer Research Studies
- Acute Myeloid Leukemia Research
- Health Systems, Economic Evaluations, Quality of Life
- Radiomics and Machine Learning in Medical Imaging
- Melanoma and MAPK Pathways
- Pharmaceutical Economics and Policy
- Economic and Financial Impacts of Cancer
- Genetics, Bioinformatics, and Biomedical Research
- Epigenetics and DNA Methylation
- Pancreatic and Hepatic Oncology Research
- Cutaneous Melanoma Detection and Management
- Genomics and Rare Diseases
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Prostate Cancer Treatment and Research
- Pancreatic function and diabetes
- Genomics, phytochemicals, and oxidative stress
- Biomedical Text Mining and Ontologies
Roche (United States)
2013-2022
La Roche College
2017-2022
AstraZeneca (Brazil)
2021
Merck (Germany)
2021
Roche (Switzerland)
2014-2021
Boehringer Ingelheim (China)
2021
Materials Systems (United States)
2013-2018
Ortho Clinical Diagnostics (United States)
2011
Johnson & Johnson (United States)
2010-2011
Hospices Civils de Lyon
2010
Cigarette smoke is the major cause of lung cancer, leading cancer death, and chronic obstructive pulmonary disease, fourth death in United States. Using high-density gene expression arrays, we describe genes that are normally expressed a subset human airway epithelial cells obtained at bronchoscopy (the transcriptome), define how cigarette smoking alters transcriptome, detail effects variables, such as cumulative exposure, age, sex, race, on smoke-induced changes expression. We also...
IntroductionThe potential to accurately quantify epidermal growth factor receptor (EGFR) mutations in plasma from non–small-cell lung cancer patients would enable more rapid and frequent analyses assess disease status; however, the utility of such for clinical purposes has only recently started explore.MethodsPlasma samples were obtained 69 with EGFR-mutated tumors 21 negative control cases. EGFR analyzed by a standardized allele-specific polymerase chain reaction (PCR) test ultra-deep...
Coding mutations in the AR (androgen receptor) gene have been identified tissue samples from patients with advanced prostate cancer and represent a possible mechanism underlying development of castration-resistant (CRPC). There is paucity tumor-derived available for molecular studies CRPC patients. Circulating tumor cells (CTCs) blood avenue interrogating disease such patients.Circulating were captured CellSearch Tumor Cell (CTC) Kit Profile plus Qiagen's AllPrep DNA/RNA Micro measurement...
Abstract Background First-line treatment for metastatic colorectal cancer (mCRC) typically entails a biologic such as bevacizumab (BEV) with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5-fluorouracil/leucovorin/irinotecan (FOLFIRI). STEAM (NCT01765582) assessed the efficacy of BEV plus FOLFOX/FOLFIRI (FOLFOXIRI), administered concurrently (cFOLFOXIRI-BEV) sequentially (sFOLFOXIRI-BEV, FOLFOX-BEV alternating FOLFIRI-BEV), versus mCRC. Patients and Methods previously untreated mCRC (n =...
Identification of predictors for overall survival (OS) allows timely detection clinical efficacy signals and therefore facilitates treatment decisions. We assessed the association between circulating tumor DNA (ctDNA) metrics primary end point OS in a subset previously treated patients with locally advanced or metastatic non-small-cell lung cancer, who underwent atezolizumab docetaxel open-label randomized phase III OAK trial.Plasma from 94 at baseline subsequent cycles therapy every 3 weeks...
Molecular biomarkers hold promise for personalization of cancer treatment. However, a typical tumor biopsy may be difficult to acquire and not capture genetic variations within or across tumors. Given these limitations, genotyping using next-generation sequencing plasma-derived circulating (ct)-DNA has the potential transform non–small cell lung (NSCLC) management. Importantly, mutations detected in biopsied tissue must also ctDNA at different disease stages. Using AVENIO Surveillance kit...
The EURTAC trial demonstrated that the tyrosine kinase inhibitor (TKI) erlotinib was superior to chemotherapy as first-line therapy for advanced non-small cell lung cancers (NSCLC) harbor EGFR activating mutations in a predominantly Caucasian population. Based on and several Asian trials, anti-EGFR TKIs are standard of care mutation-positive NSCLC. We sought validate rapid multiplex mutation assay companion diagnostic select patients this therapy. Samples from were prospectively screened...
Somatic mutations derived from the expansion of clonal populations blood cells (clonal hematopoiesis indeterminate potential, or CHIP) may be detected in sequencing cell-free DNA (cfDNA) samples. We evaluated potential implications CHIP targeted plasma samples using matched peripheral mononuclear (PBMCs) patients with lung cancer to identify CHIP-associated mutations.A total 332 and corresponding PBMC were collected predose, cycle 1 day (C1D1), randomized, phase III study (OAK) comparing...
The hyperlipidemia and hyperglycemia of the diabetic state accelerate β-cell dysfunction, yet mechanisms are not fully defined. We used rat islet-specific oligonucleotide arrays (Metabolex Rat Islet Genechips) to identify genes that coordinately regulated by high glucose free fatty acids (FFA). Exposure islets FFA (125 μm for 2 days) or (27 mm 4 reduced glucose-stimulated insulin secretion 70 ± 5 40 4%, respectively, relative control-cultured islets. These treatments also substantially...
3591 Background: Adjuvant chemotherapy is offered to most pts with Stage III CRC, and a subset II disease deemed at high-risk for recurrence. Nevertheless, risk stratification strategies remain suboptimal. Detection of minimal residual (MRD) through ctDNA analysis has been shown identify high recurrence in but not disease. Methods: The next-generation sequencing based AVENIO Surveillance Kit (Research Use Only) was used single nucleotide variants (SNVs) tumor tissue within cohort 145 CRC...
We assessed plasma circulating tumor DNA (ctDNA) level as a prognostic marker for progression-free survival (PFS) following first-line metastatic colorectal cancer (mCRC) therapy.The Sequencing Triplet With Avastin and Maintenance (STEAM) was randomized, phase II trial investigating efficacy of bevacizumab (BEV) plus 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) 5-fluorouracil/leucovorin/irinotecan (FOLFIRI), administered concurrently or sequentially, versus FOLFOX-BEV in mCRC. Evaluation...
BACKGROUND Molecular testing to determine gene mutation status is now the recommended standard of care for patients with advanced or metastatic Non‐small cell lung cancer (NSCLC). Because majority NSCLC present disease, minimally invasive procedures are necessary diagnosis, staging, and molecular analysis. However, resulting samples have perceived limitations in oncology community, most commercially available tests not been validated these sample types. The current study was undertaken...
Summary: Despite exponentially increased industry investment in oncology research and development with more than $80 billion spent annually, patient enrollment clinical trials remains below 5% globally. Our multistakeholder international cancer coalition envisions ecosystem transformation capacity building through a global “hub-and-spoke” network model to expand access accelerate trials, thus ending as major cause of death this lifetime.
To assess the molecular changes associated with pancreatic beta-cell dysfunction occurring during onset of type 2 diabetes, we profiled islet mRNAs from diabetic male and high-fat-fed female Zucker fatty (ZDF) rats their nondiabetic lean counterparts on custom islet-specific oligonucleotide arrays. The most prominent in both models diabetes were increases encoding proteases extracellular matrix components that are tissue remodeling fibrosis. for metalloproteinase (MMP)-2, -12, -14 sharply...
AIM:To assess prospectively parameters of computed tomography perfusion (CT p) for evaluation vascularity liver metastases from neuroendocrine tumors. METHODS:This study was approved by the hospital's institutional review board.All 18 patients provided informed consent.There were 30 tumors.Patients divided into three groups depending on appearance at arterial phase morphological CT (hyperdense, hypodense and necrotic).Sequential acquisition performed before 2 min after intravenous injection...
Abstract Background Identifying and tracking somatic mutations in cell-free DNA (cfDNA) by next-generation sequencing (NGS) has the potential to transform clinical management of subjects with advanced non-small cell lung cancer (NSCLC). Methods Baseline tumor tissue ( n = 47) longitudinal plasma 445) were collected from 71 NSCLC treated chemotherapy. cfDNA was enriched using a targeted-capture NGS kit containing 197 genes. Clinical responses treatment determined RECIST v1.1 correlations...
Induction by hemin increases, while induction with 12-O-tetradecanoylphorbol-13-acetate (TPA) represses, erythroid-specific gene expression in the human cell line K562. We analyzed effects of or TPA on binding and activity transcription factors at a regulatory element found within transcriptional sequences many genes. increases ubiquitous AP-1 to this element. inhibits lineage limited factor NF-E2 control Hemin K562 cells does not facilitate its recognition site. appears nonspecifically...
Advances in personalized medicine are supported by companion diagnostic molecular tests. Testing accuracy is critical for selecting patients optimal therapy and reducing treatment-related toxicity. We assessed the clinical economic impact of inaccurate test results between laboratory developed tests (LDTs) a US Food Drug Administration (FDA)-approved detection epidermal growth factor receptor (EGFR) mutations. Using hypothetical cohort newly diagnosed metastatic non-small cell lung cancer...
15–40% of non-small cell lung cancer (NSCLC) patients harbor epidermal growth factor receptor (EGFR)-sensitizing mutations. Tyrosine kinase inhibitors (TKIs) provide significant clinical benefit in this population, yet all will ultimately progress. Liquid biopsy can reliably identify somatic tumor-associated EGFR mutations plasma. This study aimed to assess the feasibility and value quantitative assessment driver plasma EGFR-mutated NSCLC treated with EGFR-TKIs as a tool evaluate therapeutic...